Aquatic Capital Management LLC Acquires 40,333 Shares of DaVita Inc. $DVA

Aquatic Capital Management LLC boosted its holdings in shares of DaVita Inc. (NYSE:DVA) by 370.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,218 shares of the company’s stock after purchasing an additional 40,333 shares during the quarter. Aquatic Capital Management LLC owned about 0.07% of DaVita worth $6,805,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita in the second quarter worth $43,000. iSAM Funds UK Ltd acquired a new position in DaVita during the 3rd quarter valued at $46,000. Employees Retirement System of Texas bought a new stake in DaVita in the 2nd quarter valued at $49,000. SJS Investment Consulting Inc. grew its position in DaVita by 3,091.7% in the 3rd quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock worth $51,000 after purchasing an additional 371 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of DaVita by 34.9% during the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock worth $59,000 after purchasing an additional 117 shares during the period. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

DVA has been the subject of several research reports. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Truist Financial set a $158.00 price target on DaVita in a research note on Thursday, February 5th. UBS Group raised their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Barclays lifted their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Finally, TD Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $155.80.

DaVita Price Performance

Shares of DaVita stock opened at $150.67 on Monday. The firm has a 50 day simple moving average of $131.81 and a 200 day simple moving average of $127.01. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The firm has a market cap of $10.06 billion, a P/E ratio of 15.20, a P/E/G ratio of 0.53 and a beta of 0.93.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.